Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
暂无分享,去创建一个
S. Walmsley | C. Orrell | Kimberly Smith | M. Aboud | B. Wynne | V. Falcó | N. Porteiro | C. Vavro | D. Hagins | C. Man | A. Buchanan | A. Aylott | E. Belonosova